

01/15/98  
U.S. PTO

Docket #: PF-0182-1 DIV

#2 | Pre-A  
A.R.  
06/06/98

"Express Mail" mailing label number EM 081 942 611 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box Sequence, Washington, D.C. 20231 on 1/15/98

By: Al Williamson  
Printed: Al Williamson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.53(b)

Assistant Commissioner for Patents

Box Sequence

Washington, D.C. 20231

Attn: Nashed, N.  
Class: 435  
Subclass: 189

Dear Sir:

This is a request for filing a **DIVISIONAL** application under 37 CFR 1.53(b) of pending prior application Serial No. **08/774,169**, filed on **December 26, 1996**, entitled: **NOVEL GUANOSINE MONOPHOSPHATE REDUCTASE**.

1.  Enclosed is a copy of the prior application, U. S. Application Serial No. **08/774,169** filed **December 26, 1996**, including the oath or declaration as originally filed.
2.  With regard to the requirement of 37 CFR 1.821(d) which requires that a copy of the Sequence Listing in computer readable form (CRF) be submitted, Applicants submit that the computer readable form of the "Sequence Listing" in the instant divisional application, is identical with that filed for Serial No. **08/774,169**, filed **December 26, 1996**, to which priority is claimed. In accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed with U.S. Application Serial No. **08/774,169** as the computer readable form for the instant divisional application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant divisional application.
3.  A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 was filed in prior application number 08/ \_\_\_\_\_ and such status is still proper and desired (37 CFR 1.28(a))
4.  Cancel in this application original claims 2-10 and 20 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

Al

5.  The inventor of the invention being claimed in this application is: Jennifer L. Hillman.

6.  In accordance with 37 CFR 1.63(d) a copy of the originally signed declaration showing applicant's signature as filed on May 16, 1997, is enclosed.

7.  Amend the specification by inserting before the first line the sentence: "This application is a divisional application of U.S. application serial number 08/774,169, filed December 26, 1996."

8.  The filing fee is calculated below:

Claims	Number Filed	Minus	Number Extra	Other Than Small Entity Rate		Basic Fee \$790.00
Total Claims	10	-20	0	x \$22		\$ 0.00
Indep. Claims	5	-3	2	x \$82		\$164.00
<u>Multiple Dependent Claim(s), if any</u>				+ \$270		\$ 0.00

**TOTAL FILING FEE \$ 954.00**

9.  An extension of time in the above-named prior application has been requested and the fees therefor have been authorized in said application.

10.  Please charge Deposit Amount No. 09-0108 in the amount of \$954.00.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Account No. 09-0108.

**Duplicate** copies of these papers are enclosed.

11.  New formal drawings are enclosed.

12.  Priority of foreign application number \_\_\_\_\_, filed on \_\_\_\_\_ in \_\_\_\_\_  
is claimed under 35 U.S.C. 119.

13.  The prior application is assigned of record to Incyte Pharmaceuticals, Inc.

14.  A preliminary amendment is enclosed.

15. Also enclosed:

16.  The power of attorney of the prior application is to:

**LUCY J. BILLINGS REG. NO. 36,749  
MICHAEL C. CERRONE REG. NO. 39,132**

- a.  The power of attorney appears in the original papers in the prior application.
- b.  Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c.  Address all future correspondence to: (May only be completed by applicant, or attorney or agent of record.)

**INCYTE PHARMACEUTICALS, INC.  
PATENT DEPARTMENT  
3174 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555, Fax: (650) 845-4166**

Date: 1/12/98

By: Lucy J. Billings  
Lucy J. Billings  
Reg. No. 36,749

- Inventor(s)
- Assignee of complete interest
- Attorney or agent of record
- Filed under 37 CFR 1.34(a)
- Registration number if acting under 37 CFR 1.34(a) \_\_\_\_\_